ClinicalTrials.gg
Not yet recruitingNCT07565935HIITpostLCDUpdated May 4, 2026

Effects of HIIT Following PTR Programme

An interventional study of Exercise in Obesity & Overweight and Type 2 Diabetes, sponsored by University of Nottingham. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by University of Nottingham · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Obesity by University of Nottingham — 5 open to participants now, 5 under way, none of them phase 3. Obesity · University of Nottingham.

Planned enrollment
10th of 17
20 · median 24
Started
2026
with 1 other
No phase
15 of 21
4 open now
Registered
20th of 21
by date

Among the 21 studies in Obesity by University of Nottingham, this one is the 10th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 20th registered.

Obesity

11,560 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 21 studies in Obesity by University of Nottingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by University of Nottingham, or all of them as a file.
02

Study summary

Caloric restriction programmes are highly effective and safe interventions for inducing rapid weight loss and improvements in glycaemic control. The landmark DiRECT study showed that 68% of people completing a caloric restriction intervention achieved remission of type 2 diabetes (T2D) by one year. Consequently, the NHS Path to Remission (PTR) programme was developed to stimulate diabetes remission in individuals that meet certain criteria. Unfortunately, long-term follow-up of the DiRECT study suggests that in the majority of participants that achieved remission, diabetes relapses within 5 years. This necessitates a focus on identifying methods to improve long-term maintenance of diabetes remission.

High-intensity interval training (HIIT) involves several brief bursts of intense exercise, interspersed with recovery breaks, and is becoming increasingly popular. HIIT can cause improvements in cardiovascular fitness, reduce blood pressure, and lower body fat content in only a fraction of the time of traditional exercise methods. Specific to T2D, HIIT has been shown to improve pancreatic beta cell function, which is critically important for maintenance of long-term diabetes remission.

This pilot study is being conducted to determine whether participating in a home-based HIIT training programme may help maintain beta cell function in individuals that have achieved diabetes remission following the NHS PTR programme. The study will take place at the Royal Derby Hospital.

The intention is to recruit 20 participants from Derbyshire or Nottinghamshire that have achieved diabetes remission in the NHS PTR programme. Participants will be recruited following discharge from the programme and allocated to either perform a HIIT training programme (intervention group), or continue with usual care (control group) for 16 weeks.

Before starting, participants will attend the research department to have initial measurements taken including bioimpedance, fasting bloods, an intravenous glucose tolerance test, muscle ultrasound, electromyography and cardiopulmonary exercise testing. Following this, those in the intervention group will be asked to perform a home-based HIIT training programme 3 times per week and record details of each session in a booklet. The control group will be asked to continue with their habitual levels of physical activity. Participants will be contacted regularly to ensure their safety and compliance.

03

Conditions studied

  • Obesity & Overweight
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults between the age of 18-70 years
  • Ability to provide
  • Completed the NHS Path to Remission programme and achieved diabetes remission ( \<48mmol/mol (6.5%), and off diabetes medications for at least three months)

Exclusion criteria

Exclusion Criteria:

  • > 40kg/m2
  • Current participation in a formal exercise regime
  • Current pregnancy or breastfeeding
  • Uncontrolled hypertension (blood pressure >160/100mmHg)
  • History of cardiovascular disease:

    • Symptomatic angina
    • Heart failure (class III/IV)
    • Significant arrhythmias
    • Right to left cardiac shunt
    • Recent acute coronary syndrome
    • Severe aortic valvular disease
    • Active cardiac infection
  • Background of the following respiratory diseases:

    • Pulmonary hypertension
    • Significant
    • Uncontrolled asthma
  • History of undergoing current treatment or palliation
  • Presence of significant musculoskeletal, neurological or cerebrovascular disease
  • Any other medical condition deemed by the investigators to preclude inclusion into the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    HIIT group

    This group will perform 16 weeks of high-intensity interval training. This will involve performing a 15-minute routine, three times a week. The exercise programme includes star jumps, standing squats, on-the-spot sprints, then repeating standing squats and star jumps again (this pyramid design has been chosen as it can be used to provide participants with a target of repetitions to achieve in the 4th and 5th interval).

    Behavioral: Exercise

  • No intervention
    Control group

    This is the control group and will be asked to perform their usual habitual levels of activity for the 16 weeks of the study.

Interventions

  • BehavioralExercise

    High-intensity interval training

06

What researchers measure

Primary outcomes

  1. Pancreatic beta cell function

    Assessment of beta-cell function using insulin first phase response from an intravenous glucose tolerance test

    Time frame: Assessed at baseline and then follow-up (16 weeks)

Secondary outcomes

  1. Insulin sensitivity

    Measured during the intravenous glucose tolerance test (IVGTT) and calculated from fasting glucose and insulin using the homeostatic model of assessment for insulin resistance

    Time frame: Assessed at baseline and then follow-up (16 weeks)

  2. Overall glycaemic control

    From measurement of glycated haemoglobin (HbA1c)

    Time frame: Assessed at baseline and then follow-up (16 weeks)

  3. Body weight

    Measurement of participant weight

    Time frame: Assessed at baseline and then follow-up (16 weeks)

  4. Body composition

    Measurement of fat mass and fat-free mass using bioimpedance analysis

    Time frame: Assessed at baseline and then follow-up (16 weeks)

  5. Skeletal muscle function

    Assessed using muscle strength (1 repetition maximum) testing and electromyography

    Time frame: Assessed at baseline and then follow-up (16 weeks)

  6. Skeletal muscle structure

    Using muscle ultrasonography to assess muscle thickness, cross sectional area and fibre pennation angle

    Time frame: Assessed at baseline and then follow-up (16 weeks)

  7. Cardiorespiratory fitness

    Determined from be the highest rate of oxygen consumption obtained (VO2max) during a cardiopulmonary exercise test

    Time frame: Assessed at baseline and then follow-up (16 weeks)

07

Study locations

1 site
  • University of Nottingham, Royal Derby Hospital Centre
    Derby, DE22 3DT, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Jan 2027, 8 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 8 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
May 4, 2026
StartEst.
May 2026
Primary completionEst.
Jan 2027
CompletionEst.
May 2027
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07565935
Collaborators
Association of British Clinical Diabetologists
Responsible party
Sponsor
First posted
May 4, 2026
Start date
May 2026 (estimated)
Primary completion
Jan 2027 (estimated)
Completion
May 2027 (estimated)
Last update
May 4, 2026

Study contacts

Oluwaseun Anyiam
Contact
oluwaseun.anyiam1@nottingham.ac.uk
+441332724605
Iskandar Idris
principal investigator · University of Nottingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion